Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 3/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.32 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6126212 | 0.94 | AR (0.40) | ARPLK1CCNA2CDK2CCNA1 | |
| SCHEMBL6126541 | 0.89 | HPGD (0.37) | ARSYKKMT2AL3MBTL1PIK3CA | |
| Hydrochloric Acid SCHEMBL6117543 | 0.88 | HPGD (0.36) | ARSYKKMT2AL3MBTL1PIK3CA | |
| SCHEMBL8278500 | 0.87 | SYK (0.36) | ARDYRK1AMAPK14SYK | |
| Hydrochloric Acid SCHEMBL6118017 | 0.86 | SYK (0.36) | ARDYRK1AMAPK14SYK | |
| SCHEMBL8277683 | 0.85 | NPC1 (0.33) | KMT2ACCNA2CDK2 | |
| SCHEMBL8277641 | 0.84 | PLK1 (0.35) | ARDYRK1APLK1SYKKMT2A | |
| SCHEMBL8277560 | 0.79 | SYK (0.37) | ARDYRK1AMAPK14SYK | |
| SCHEMBL8278565 | 0.79 | PLK1 (0.39) | DYRK1APLK1CCNA2CDK2CCNA1 | |
| SCHEMBL8278710 | 0.79 | TNNI3K (0.37) | PLK1KMT2ACCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129811-A1 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP3, MMP13 | AR 4023/4885DYRK1A 4569/4885PLK1 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.